Results 11 to 20 of about 5,090 (179)

Talimogene laherparepvec: First in class oncolytic virotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2018
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at ...
Robert M. Conry, Brian Westbrook, Svetlana McKee, Timothy Graham Norwood   +3 more
doaj   +5 more sources

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma [PDF]

Head and Neck, 2016
BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene ...
Agarwala, Sanjiv S., Amatruda, Thomas, Andtbacka, Robert H. I., Chen, Lisa, Hallmeyer, Sigrun, Harrington, Kevin J., Kaufman, Howard L., Milhem, Mohammed, Nemunaitis, John J., Ollila, David W., Ross, Merrick, Shilkrut, Mark   +11 more
core   +8 more sources

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma [PDF]

Journal for ImmunoTherapy of Cancer
Background Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness ...
Shailender Bhatia, Paul T Nghiem, George Ansstas, Song Y Park, Coley Doolittle-Amieva, Evan T Hall, Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, David Y Chen   +10 more
doaj   +2 more sources

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS) [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background Oncolytic virus therapy is a rapidly evolving emerging approach for the medical management of cancer. Talimogene laherparepvec (T-VEC) is the first and only Food and Drug Administration (FDA)-approved oncolytic virus therapy.
Yifan Hong, Kebin Cheng, Han Qu, Yuting Wang, Yuanyuan Wang, Guorong Fan, Zhenghua Wu   +6 more
doaj   +2 more sources

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. [PDF]

Oncologist
BACKGROUND: Newer effective therapies are needed for patients with solid tumors with liver metastases and unresectable hepatocellular carcinoma (HCC). METHODS: Part 1 (dose exploration) evaluated intrahepatic talimogene laherparepvec (T-VEC) injection in
Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K, Hamidi A, Chesney J.   +12 more
europepmc   +6 more sources

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. [PDF]

J Clin Oncol, 2023
Purpose: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H.   +28 more
europepmc   +2 more sources

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec [PDF]

JAAD Case Reports, 2023
Erin M. McClure, BS, Neha Singh, BS, Kim G. Abson, MD, MPH, Shailender Bhatia, MD, Heidi J. Gray, MD, Laura S. Brown, PhD, ABPP, Ata S. Moshiri, MD, MPH   +6 more
doaj   +2 more sources

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)

Melanoma Management, 2019
Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice.
Matthew C Perez, Jonathan S Zager, Thomas Amatruda, Robert Conry, Charlotte Ariyan, Anupam Desai, John M Kirkwood, Sheryl Treichel, David Cohan, Leon Raskin   +9 more
doaj   +3 more sources

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition [PDF]

Journal for ImmunoTherapy of Cancer, 2018
Background Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management of patients progressing
Zoë Blake, Douglas K. Marks, Robyn D. Gartrell, Thomas Hart, Patti Horton, Simon K. Cheng, Bret Taback, Basil A. Horst, Yvonne M. Saenger   +8 more
doaj   +3 more sources

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec [PDF]

JAAD Case Reports, 2023
Jamie Lebhar, BME, Jennifer Jacobs, BS, Khushnood Faraz, BS, April K.S. Salama, MD, Paul J. Mosca, MD, PhD, MBA   +4 more
doaj   +2 more sources